Condition
Search result for "Solr search content"
Search Result for "multiple myeloma"
Clinical Trial
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib, and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM
To compare the progression-free survival (PFS) of mezigdomide (CC-92480, also known as BMS-986348), bortezomib and dexamethasone (MeziVd) to that of pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)
Blood Cancer Program
Blood Cancer Program
provider
Matthew Butler, MD Hematology-Oncology, Internal Medicine
Story
Excellence in nursing: Amy Cantu, RN, earns 2023-2024 Gold Shield Award
Amy Cantu, RN, has been awarded the prestigious 2023-2024 Gold Shield Clinical Award for her exemplary dedication and outstanding nursing skills.
provider
Shammi Anholt, MSPT, CLT-LANA Oncology Rehabilitation , Lymphedema Management
provider
Edward Medina, M.D. Clinical Pathology, Hematopathology
provider